Cargando…

Human papillomavirus 16L1-58L2 chimeric virus-like particles elicit durable neutralizing antibody responses against a broad-spectrum of human papillomavirus types

The neutralizing antibodies elicited by human papillomavirus (HPV) major capsid protein L1 virus-like particle (VLP)-based vaccines are largely type-specific. An HPV vaccine inducing cross-neutralizing antibodies broadly will be cost-effective and of great value. To this end, we constructed HPV16L1-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xue, Liu, Hongyang, Wang, Zhirong, Wang, Shuo, Zhang, Ting, Hu, Meili, Qiao, Liang, Xu, Xuemei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609925/ https://www.ncbi.nlm.nih.gov/pubmed/28968993 http://dx.doi.org/10.18632/oncotarget.19327

Ejemplares similares

A novel C-terminal modification method enhanced the yield of human papillomavirus L1 or chimeric L1-L2 virus-like particles in the baculovirus system
por: Ma, Mingrao, et al.
Publicado: (2023)

Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58
por: Brendle, Sarah A., et al.
Publicado: (2010)

A Vaccine of L2 Epitope Repeats Fused with a Modified IgG1 Fc Induced Cross-Neutralizing Antibodies and Protective Immunity against Divergent Human Papillomavirus Types
por: Chen, Xue, et al.
Publicado: (2014)

Ancient Evolution and Dispersion of Human Papillomavirus 58 Variants
por: Chen, Zigui, et al.
Publicado: (2017)

VLPs Displaying a Single L2 Epitope Induce Broadly Cross-Neutralizing Antibodies against Human Papillomavirus
por: Tumban, Ebenezer, et al.
Publicado: (2012)

Structural Basis for the Shared Neutralization Mechanism of Three Classes of Human Papillomavirus Type 58 Antibodies with Disparate Modes of Binding
por: He, Maozhou, et al.
Publicado: (2021)

Replication and transcription of human papillomavirus type 58 genome in Saccharomyces cerevisiae
por: Li, Jing, et al.
Publicado: (2010)

Role of L2 cysteines in papillomavirus infection and neutralization
por: Gambhira, Ratish, et al.
Publicado: (2009)

Stability of trivalent human papillomavirus (types 16, 18, 58) recombinant vaccine (Escherichia coli)
por: Liu, Yu-Ying, et al.
Publicado: (2021)

Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma
por: Baboci, Lorena, et al.
Publicado: (2013)

Oncogenic comparison of human papillomavirus type 58 E7 variants
por: Law, Priscilla TY, et al.
Publicado: (2018)

Cross-Neutralization Potential of Native Human Papillomavirus N-Terminal L2 Epitopes
por: Conway, Michael J., et al.
Publicado: (2011)

E6 and E7 Gene Polymorphisms in Human Papillomavirus Types-58 and 33 Identified in Southwest China
por: Chen, Zuyi, et al.
Publicado: (2017)

Delta breakthrough infections elicit potent, broad and durable neutralizing antibody responses
por: Walls, Alexandra C., et al.
Publicado: (2021)

Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV)
por: Huber, Bettina, et al.
Publicado: (2017)

Human papillomavirus type 58: the unique role in cervical cancers in East Asia
por: Chan, Paul KS
Publicado: (2012)

Distribution of Human Papillomavirus 52 and 58 Genotypes, and Their Expression of p16 and p53 in Cervical Neoplasia
por: Kim, Tae Eun, et al.
Publicado: (2014)

Differential expression of human papillomavirus 16-, 18-, 52-, and 58-derived transcripts in cervical intraepithelial neoplasia
por: Baba, Satoshi, et al.
Publicado: (2020)

Ancient Evolutionary History of Human Papillomavirus Type 16, 18 and 58 Variants Prevalent Exclusively in Japan
por: Tanaka, Kohsei, et al.
Publicado: (2022)

Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles
por: Yang, Fan, et al.
Publicado: (2020)

Correction: E6 and E7 Gene Polymorphisms in Human Papillomavirus Types-58 and 33 Identified in Southwest China
por: Chen, Zuyi, et al.
Publicado: (2017)

Optimization of Multimeric Human Papillomavirus L2 Vaccines
por: Jagu, Subhashini, et al.
Publicado: (2013)

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)

Human Papillomavirus Type16- L1 VLP Production in Insect Cells
por: Abdoli, Asghar, et al.
Publicado: (2013)

A broadly protective vaccine against cutaneous human papillomaviruses
por: Mariz, Filipe Colaco, et al.
Publicado: (2022)

Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants
por: Matić, Slavica, et al.
Publicado: (2011)

Epitomics: IgG-epitome decoding of E6, E7 and L1 proteins from oncogenic human papillomavirus type 58
por: Xu, Wan-Xiang, et al.
Publicado: (2016)

Prevalence of Human Papillomavirus Type 58 in Women With or Without Cervical Lesions in Northeast Brazil
por: Fernandes, JV, et al.
Publicado: (2013)

Substitution of Human Papillomavirus Type 16 L2 Neutralizing Epitopes Into L1 Surface Loops: The Effect on Virus-Like Particle Assembly and Immunogenicity
por: Chabeda, Aleyo, et al.
Publicado: (2019)

Antibodies to Human Papillomavirus 16, 18, 58, and 6b Major Capsid Proteins among Japanese Females
por: Matsumoto, Koji, et al.
Publicado: (1997)

Multivalent Human Papillomavirus L1 DNA Vaccination Utilizing Electroporation
por: Kwak, Kihyuck, et al.
Publicado: (2013)

Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies
por: Combelas, Nicolas, et al.
Publicado: (2010)

Human papillomaviruses 16 and 58 are distributed widely among women living in Shanghai, China, with high-grade, squamous intraepithelial lesions
por: Xu, J., et al.
Publicado: (2018)

Meta-Analysis on Prevalence and Attribution of Human Papillomavirus Types 52 and 58 in Cervical Neoplasia Worldwide
por: Chan, Paul K. S., et al.
Publicado: (2014)

A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine
por: Yih, W Katherine, et al.
Publicado: (2021)

Measurement of Neutralizing Serum Antibodies of Patients Vaccinated with Human Papillomavirus L1 or L2-Based Immunogens Using Furin-Cleaved HPV Pseudovirions
por: Wang, Joshua W., et al.
Publicado: (2014)

Maturation of the Human Papillomavirus 16 Capsid
por: Cardone, Giovanni, et al.
Publicado: (2014)

Prevalence of Human Papillomavirus Variants and Genetic Diversity in the L1 Gene and Long Control Region of HPV16, HPV31, and HPV58 Found in North-East Brazil
por: Gurgel, Ana Pavla Almeida Diniz, et al.
Publicado: (2015)

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2022)

A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
por: Weidenbacher, Payton A.-B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6ddqr29mh55kplu1kumlmp0eue